Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
May 22, 2018 02:00 ET
|
Spark Therapeutics, Inc.
Annualized bleeding rate (ABR) for all 15 participants was reduced by 98 percent, while annualized infusion rate (AIR) was reduced by 99 percent as of the May 7, 2018 data cutoff Range of...
Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress
May 08, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, May 08, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights
May 01, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, May 01, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
Spark Therapeutics Sells Priority Review Voucher for $110 Million
April 30, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, April 30, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics to Participate in Multiple Conferences in March
February 23, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress
February 20, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights
February 13, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
Spark Therapeutics to Participate in Multiple Conferences in February
February 05, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.
January 24, 2018 16:00 ET
|
Spark Therapeutics, Inc.
Novartis Pharmaceuticals will commercialize investigational voretigene neparvovec when and if approved in Europe and all other markets outside the U.S.; Spark Therapeutics retains U.S. commercial...
Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors
January 04, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...